Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03558048 · ClinicalTrials.gov registry record

The Effect of IBD Flares on Serum PSA

A clinical trial of Prostate Cancer and Inflammatory Bowel Diseases, sponsored by Northwestern University.

Recruiting
Registry status
400
Enrollment target
1
Study location

NCT03558048 is a study of Prostate Cancer and Inflammatory Bowel Diseases that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 400 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03558048, a study of Prostate Cancer and Inflammatory Bowel Diseases, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
400 participants
Enrollment target
1
Study location

Study Summary

This study will measure Prostate Specific Antigen (PSA) values in men with Inflammatory Bowel Disease (IBD) before, during, and following a flare. In addition, the effect of any PSA increase will be analyzed and correlated to the location of disease (rectal vs. other). Study findings may help men with IBD by identifying pitfalls in prostate cancer screening for this population and help to stratify and understand the effect IBD has on the prostatic milieu. By optimizing how men with IBD are screened for prostate cancer, future unnecessary healthcare encounters and expenditures may be reduced for this patient group.

Interventions

  • DIAGNOSTIC_TEST Blood draw

Study Locations (1)

Illinois

  • Northwestern Medicine - Chicago

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2019-08-01
Est. Completion 2025-10-01

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT03558048

The ClinicalTrials.gov registry entry for NCT03558048 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (34% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.

NCT03558048 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT03558048 about?

NCT03558048 is a clinical study titled "The Effect of IBD Flares on Serum PSA". This study will measure Prostate Specific Antigen (PSA) values in men with Inflammatory Bowel Disease (IBD) before, during, and following a flare. In addition, the effect of any PSA increase will be analyzed and correlated to the location of disease (rectal vs. other). Study findings may help men wi...

What is the current status of trial NCT03558048?

This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2019-08-01. Estimated completion is 2025-10-01.

What conditions does trial NCT03558048 study?

This clinical trial studies the following conditions: Prostate Cancer, Inflammatory Bowel Diseases.

What interventions are being tested in trial NCT03558048?

The interventions under investigation include: Blood draw (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03558048?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03558048 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.